EUVIMEDEUVIMED entdecken
Crossref

Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry

Carly Grant, Lourdes M Perez-Chada, Ryan W Harrison, Robert R McLean, Blessing Dube, Margaux M Crabtree, Alice B Gottlieb, Joseph F Merola

Clinical and Experimental Dermatology · 2024

DOI: 10.1093/ced/llae095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Carly Grant und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Registries, Psoriasis. Die Arbeit nennt 31 Literaturangaben. Gefördert von: National Psoriasis Foundation, CorEvitas LLC, Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early identification, diagnosis and symptom control of psoriatic arthritis (PsA) in patients with psoriasis remain unmet medical needs.

Objectives

To compare the impact of disease and other characteristics between patients with psoriasis who screened positive for PsA using the Psoriasis Epidemiology Screening Tool (PEST) (screen-positive group) and patients who (i) have PsA (PsA group) or (ii) screened negative for PsA (screen-negative group). Also, to determine the proportion of patients at a patient-acceptable symptom state (PASS) in the screen-positive and PsA groups.

Methods

This was a cross-sectional analysis of the CorEvitas Psoriasis Registry. We included a convenience sample of patients with psoriasis from the screen-positive and PsA groups who completed the Psoriatic Arthritis Impact of Disease-12 (PsAID12), and a comparator screen-negative group who did not complete the PsAID12. We report descriptive summaries of demographics, comorbidities, psoriasis characteristics, patient-reported outcome measures and the proportion of patients at PASS (i.e. PsAID12 ≤ 4).

Results

The screen-positive, PsA and screen-negative groups included 369, 70 and 4724 patients, respectively. The screen-positive and PsA groups had a similar impact of disease, demographics, comorbidities and psoriasis characteristics (d < 0.337). Mean PsAID12 scores were 3.1 (SD 2.3) and 3.7 (SD 2.6) in the screen-positive and PsA groups, respectively. Compared with patients who screened negative for PsA, patients who screened positive exhibited higher rates of selected known predictors of PsA such as older age, longer psoriasis duration, nail disease and inverse psoriasis. The proportion of patients at PASS was 56% and 67% for the PsA and screen-positive groups, respectively.

Conclusions

The similar profiles between screen-positive and PsA groups, in comparison with the screen-negative group, support observations of possible underdiagnosis of PsA and the increased impact of disease, especially musculoskeletal disease, among patients who screen positive for PsA. The high percentage of patients not at an acceptable symptom state in the PsA and screen-positive groups highlights the need to optimize care in PsA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticRegistriesPsoriasisHumansCross-Sectional StudiesMaleFemaleMiddle AgedAdultPatient Reported Outcome MeasuresAgedSeverity of Illness Index

Autor:innen und Institutionen

  • Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • CorEvitas LLC, Waltham, MA, USA.
  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Division of Rheumatology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Förderung

  • National Psoriasis Foundation
  • CorEvitas LLC
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Janssen Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc
  • Sanofi, Sun Pharmaceutical Industries Ltd and UCB S.A.

Zitieren

APA

Grant, C., Perez-Chada, L. M., Harrison, R. W., McLean, R. R., Dube, B., Crabtree, M. M., Gottlieb, A. B., & Merola, J. F. (2024). Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae095

Vancouver

Grant C, Perez-Chada LM, Harrison RW, McLean RR, Dube B, Crabtree MM, et al. Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae095

BibTeX
@article{Grant2024,
  author = {Grant, Carly and Perez-Chada, Lourdes M and Harrison, Ryan W and McLean, Robert R and Dube, Blessing and Crabtree, Margaux M and Gottlieb, Alice B and Merola, Joseph F},
  title = {Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  doi = {10.1093/ced/llae095}
}
Kostenlos starten →